| 21 Aug, 08:52 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 21 Aug, 08:52 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package". | nse |
| 20 Aug, 08:53 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 20 Aug, 08:52 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray". | nse |
| 13 Aug, 09:34 pm | — | … | Letter to shareholders whose email address are not registered providing the Web Link of Integrated Annual Report | nse |
| 13 Aug, 08:11 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Reg. 34 (1) Annual Report. | bse |
| 11 Aug, 10:33 pm | — | … | Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 | nse |
| 10 Aug, 03:00 pm | — | … | Intimation of Allotment of shares under the Employee Stock Option Plan 2016 | nse |
| 05 Aug, 04:08 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | bse |
| 05 Aug, 04:04 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Transcript | nse |
| 03 Aug, 04:30 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 03 Aug, 04:16 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Link of Recording | nse |
| 31 Jul, 07:19 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 31 Jul, 07:19 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investor Presentation'. | nse |
| 31 Jul, 07:12 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Press Release and Management Discussion & Analysis". | nse |
| 31 Jul, 07:12 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 31 Jul, 07:02 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 List of Officials'. | nse |
| 31 Jul, 06:53 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 31-Aug-2026. | nse |
| 31 Jul, 06:42 pm | — | … | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. | nse |
| 31 Jul, 06:38 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Outcome for Board Meeting Outcome - Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026 | bse |
| 28 Jul, 10:41 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 28, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials". | nse |
| 28 Jul, 10:39 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 21 Jul, 08:43 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 21 Jul, 08:41 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 21, 2026, titled "Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years". | nse |
| 15 Jul, 03:30 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of Glenmark Pharmaceuticals Limited For The Quarter Ended June 30, 2026 | bse |
| 06 Jul, 08:36 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 06, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial". | nse |
| 06 Jul, 08:36 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 02 Jul, 08:36 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 02 Jul, 08:35 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer". | nse |
| 30 Jun, 10:01 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 | bse |
| 30 Jun, 10:00 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about U.S. FDA inspection | nse |
| 17 Jun, 08:38 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 17 Jun, 08:37 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 17, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial". | nse |
| 11 Jun, 10:20 am | other | 2 | Glenmark Pharmaceuticals launched Winlevi (clascoterone) 10 mg/g cream in key European markets for the treatment of acne vulgaris. | nse |
| 09 Jun, 04:52 pm | investor_meet | 1 | Glenmark Pharmaceuticals Limited informed the exchange about an investor presentation. | nse |
| 05 Jun, 09:00 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | bse |
| 05 Jun, 08:48 am | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 05, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials". | nse |
| 05 Jun, 08:46 am | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 01 Jun, 05:27 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Link of Recording | nse |
| 01 Jun, 05:24 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 29 May, 10:28 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation | nse |
| 29 May, 10:24 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 29 May, 10:12 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 29 May, 09:59 pm | — | … | Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the Press Release and Management Discussion & Analysis of the Company for the Fourth Quarter ended March 31, 2026. | nse |
| 29 May, 09:12 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP | nse |
| 29 May, 08:53 pm | — | … | The Board of Directors, at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ( GHL ), a wholly owned subsidiary of the Company. | nse |
| 29 May, 08:46 pm | — | … | The Board at its meeting held today i.e. May 29, 2026 have approved Early Retirement of Company Secretary & Compliance Officer, Appointment of Company Secretary & Compliance Officer and Appointment of Senior Management Personne | nse |
| 29 May, 08:42 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Change in Management | bse |
| 29 May, 08:23 pm | — | … | Glenmark Pharmaceuticals Ltd - 532296 - Corporate Action-Board to consider Dividend | bse |
| 29 May, 08:20 pm | — | … | Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. | nse |